RenovoRx (RNXT) Stock Price, News & Analysis

Company Overview

RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for difficult-to-treat solid tumors. The company’s approach is designed to deliver cancer therapies directly to tumors through the arterial blood supply, with the goal of improving local drug exposure while limiting systemic toxicity.

RenovoRx’s lead technology is Trans-Arterial Micro-Perfusion (TAMP), which uses the company’s RenovoCath delivery system to administer therapeutic agents directly into tumor tissue. RenovoCath is a specialized catheter intended for localized drug delivery through the peripheral vasculature. The company has primarily advanced TAMP-based treatment for locally advanced pancreatic cancer, including the investigational combination of intra-arterial gemcitabine followed by external-beam radiation therapy.

RenovoRx was founded in 2016 and is headquartered in San Jose, California. Its clinical development activities have centered on the United States, where the company has conducted studies evaluating its technology in pancreatic cancer. The company is led by Chief Executive Officer Shaun Bagai, who has experience in healthcare and medical-device commercialization.

Key Stats

• Today's Range: $1.58 to $1.77
• 50-Day Range: $0.85 to $2.52
• 52-Week Range: $0.70 to $2.59
• Volume: 634,927 shs
• Average Volume: 460,390 shs
• Market Capitalization: $78.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

RenovoRx Stock Analysis - MarketRank™

RenovoRx scored higher than 68% of companies evaluated by MarketBeat, and ranked 255th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

RenovoRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

RenovoRx has a consensus price target of $8.50, representing about 397.4% upside from its current price of $1.71.

Amount of Analyst Coverage

RenovoRx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for RenovoRx are expected to grow in the coming year, from ($0.24) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of RenovoRx is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RenovoRx is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

RenovoRx has a P/B Ratio of 11.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.06% of the float of RenovoRx has been sold short.

Short Interest Ratio / Days to Cover

RenovoRx has a short interest ratio ("days to cover") of 0.48, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RenovoRx has recently decreased by 35.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RenovoRx does not currently pay a dividend.

Dividend Growth

RenovoRx does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.44

News Sentiment

RenovoRx has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for RenovoRx this week, compared to 3 articles on an average week.

Search Interest

11 people have searched for RNXT on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added RenovoRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, RenovoRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.40% of the stock of RenovoRx is held by insiders.

Percentage Held by Institutions

3.10% of the stock of RenovoRx is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/17/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:RNXT
• CIK: 1574094
• Web: www.renovorx.com
• Phone: (408) 800-2649
• Fax: 650-397-4433
• Employees: 17
• Year Founded: 2012

Price Target and Rating

• Average Price Target for RenovoRx: $8.50
• High Price Target: $14.00
• Low Price Target: $3.00
• Potential Upside/Downside: +391.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.17 million
• Net Margins: -621.71%
• Pretax Margin: -621.71%
• Return on Equity: -135.11%
• Return on Assets: -101.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.74
• Quick Ratio: 5.53

Sales & Book Value

• Annual Sales: $1.12 million
• Price / Sales: 69.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 11.53

Miscellaneous

• Outstanding Shares: 45,130,000
• Free Float: 40,888,000
• Market Cap: $78.07 million
• Optionable: Not Optionable
• Beta: 1.12